Publications by authors named "Steven Elmore"

Claim this Profile
E
Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers.
Ahmed Hamed Salem, Zhi-Fu Tao, Orlando F Bueno, Jie Chen, Shuang Chen, Steven W Elmore

Mol Cancer Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Design of A-1293102, a Potent and Selective BCL-X Inhibitor.
Zhi-Fu Tao, Xilu Wang, Jun Chen, Justin P Ingram, Sha Jin, Steven W Elmore

ACS Med Chem Lett· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X Inhibitor.
Le Wang, George A Doherty, Andrew S Judd, Zhi-Fu Tao, T Matthew Hansen, Steven W Elmore

ACS Med Chem Lett· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
Keith F McDaniel, Le Wang, Todd Soltwedel, Steven D Fidanze, Lisa A Hasvold, Steven W Elmore

J Med Chem· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.
Mai H Bui, Xiaoyu Lin, Daniel H Albert, Leiming Li, Lloyd T Lam, Steven W Elmore

Cancer Res· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methylpyrrole inhibitors of BET bromodomains.
Lisa A Hasvold, George S Sheppard, Le Wang, Steven D Fidanze, Dachun Liu, Steven W Elmore

Bioorg Med Chem Lett· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.
Le Wang, John K Pratt, Todd Soltwedel, George S Sheppard, Steven D Fidanze, Steven W Elmore

J Med Chem· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
Yu Xiao, Paul Nimmer, George S Sheppard, Milan Bruncko, Paul Hessler, Steven W Elmore

Mol Cancer Ther· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity.
Milan Bruncko, Le Wang, George S Sheppard, Darren C Phillips, Stephen K Tahir, Steven W Elmore

J Med Chem· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.
Milan Bruncko, Le Wang, George S Sheppard, Darren C Phillips, Stephen K Tahir, Steven W Elmore

J Med Chem· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Joel D Leverson, Darren C Phillips, Michael J Mitten, Erwin R Boghaert, Dolores Diaz, Steven W Elmore

Sci Transl Med· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.
Zhi-Fu Tao, Lisa Hasvold, Le Wang, Xilu Wang, Andrew M Petros, Steven W Elmore

ACS Med Chem Lett· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.
Michael F T Koehler, Philippe Bergeron, Edna F Choo, Kevin Lau, Chudi Ndubaku, Steven W Elmore

ACS Med Chem Lett· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Andrew J Souers, Joel D Leverson, Erwin R Boghaert, Scott L Ackler, Nathaniel D Catron, Steven W Elmore

Nat Med· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.
Jun Chen, Sha Jin, Vivek Abraham, Xiaoli Huang, Bernard Liu, Steven W Elmore

Mol Cancer Ther· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
Wyndham H Wilson, Owen A O'Connor, Myron S Czuczman, Ann S LaCasce, John F Gerecitano, Steven W Elmore

Lancet Oncol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-aryl-benzimidazolones as novel small molecule HSP90 inhibitors.
Milan Bruncko, Stephen K Tahir, Xiaohong Song, Jun Chen, Hong Ding, Steven W Elmore

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR.
Andrew M Petros, Jeffrey R Huth, Thorsten Oost, Cheol-Min Park, Hong Ding, Steven W Elmore

Bioorg Med Chem Lett· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.
Scott Ackler, Michael J Mitten, Kelly Foster, Anatol Oleksijew, Marion Refici, Steven W Elmore

Cancer Chemother Pharmacol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity.
Philip D Bardwell, Jijie Gu, Donna McCarthy, Craig Wallace, Shaughn Bryant, Steven W Elmore

J Immunol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
Cheol-Min Park, Milan Bruncko, Jessica Adickes, Joy Bauch, Hong Ding, Steven W Elmore

J Med Chem· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.
Dimitra Micha, Jeff Cummings, Alex Shoemaker, Steven Elmore, Kelly Foster

Clin Cancer Res· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo.
Scott Ackler, Yu Xiao, Michael J Mitten, Kelly Foster, Anatol Oleksijew, Steven W Elmore

Mol Cancer Ther· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models.
Alex R Shoemaker, Michael J Mitten, Jessica Adickes, Scott Ackler, Marion Refici, Steven W Elmore

Clin Cancer Res· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Christin Tse, Alexander R Shoemaker, Jessica Adickes, Mark G Anderson, Jun Chen, Steven W Elmore

Cancer Res· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis